IRIS Accounts Production v23.2.0.158 09302382 Board of Directors 1.3.22 28.2.23 28.2.23 16.11.23 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh093023822022-02-28093023822023-02-28093023822022-03-012023-02-28093023822021-02-28093023822021-03-012022-02-28093023822022-02-2809302382ns10:Originalns15:EnglandWales2022-03-012023-02-2809302382ns14:PoundSterlingns10:Original2022-03-012023-02-2809302382ns10:Originalns10:Director12022-03-012023-02-2809302382ns10:Original2022-03-012023-02-2809302382ns10:Original2023-02-2809302382ns10:Originalns10:PrivateLimitedCompanyLtd2022-03-012023-02-2809302382ns10:Originalns10:SmallEntities2022-03-012023-02-2809302382ns10:Originalns10:Audited2022-03-012023-02-2809302382ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-03-012023-02-2809302382ns10:SmallCompaniesRegimeForAccountsns10:Original2022-03-012023-02-2809302382ns10:Originalns10:FullAccounts2022-03-012023-02-2809302382ns10:Originalns10:OrdinaryShareClass12022-03-012023-02-2809302382ns10:Originalns10:Director22022-03-012023-02-2809302382ns10:CompanySecretary1ns10:Original2022-03-012023-02-2809302382ns10:Originalns10:RegisteredOffice2022-03-012023-02-2809302382ns10:Original2022-02-2809302382ns10:Originalns5:CurrentFinancialInstruments2023-02-2809302382ns10:Originalns5:CurrentFinancialInstruments2022-02-2809302382ns5:ShareCapitalns10:Original2023-02-2809302382ns5:ShareCapitalns10:Original2022-02-2809302382ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-02-2809302382ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-02-2809302382ns10:Original2021-03-012022-02-2809302382ns10:Originalns5:PlantMachinery2022-02-2809302382ns10:Originalns5:PlantMachinery2022-03-012023-02-2809302382ns10:Originalns5:PlantMachinery2023-02-2809302382ns10:Originalns5:PlantMachinery2022-02-2809302382ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-02-2809302382ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-02-2809302382ns10:Originalns10:OrdinaryShareClass12023-02-2809302382ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-02-2809302382ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-03-012023-02-28
REGISTERED NUMBER: 09302382 (England and Wales)












Financial Statements

for the Year Ended 28 February 2023

for

EPI-USE Labs Limited

EPI-USE Labs Limited (Registered number: 09302382)






Contents of the Financial Statements
for the Year Ended 28 February 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


EPI-USE Labs Limited

Company Information
for the Year Ended 28 February 2023







DIRECTORS: E Jones
R J Patrick



SECRETARY: E Jones



REGISTERED OFFICE: Suite 11n-B, Trafford House Chester Road
Stretford
Manchester
M32 0RS



REGISTERED NUMBER: 09302382 (England and Wales)



SENIOR STATUTORY
AUDITOR:
Ashfaq Sharif BA FCA CTA



AUDITORS: PB Associates
Chartered Accountants and Chartered Tax Advisers
2 Castle Business Village
Station Road
Hampton
Middlesex
TW12 2BX

EPI-USE Labs Limited (Registered number: 09302382)

Balance Sheet
28 February 2023

28.2.23 28.2.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 63,584 54,618

CURRENT ASSETS
Debtors 5 3,644,418 2,019,908
Cash at bank 793,245 1,373,076
4,437,663 3,392,984
CREDITORS
Amounts falling due within one year 6 2,428,381 1,606,522
NET CURRENT ASSETS 2,009,282 1,786,462
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,072,866

1,841,080

PROVISIONS FOR LIABILITIES 11,519 11,519
NET ASSETS 2,061,347 1,829,561

CAPITAL AND RESERVES
Called up share capital 7 100 100
Retained earnings 8 2,061,247 1,829,461
SHAREHOLDERS' FUNDS 2,061,347 1,829,561

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 16 November 2023 and were signed on its behalf by:





E Jones - Director


EPI-USE Labs Limited (Registered number: 09302382)

Notes to the Financial Statements
for the Year Ended 28 February 2023

1. STATUTORY INFORMATION

EPI-USE Labs Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention and are presented in sterling.

Turnover
Turnover represents net invoiced sales of goods and services, excluding value added tax, except in respect of service contracts where turnover is recognised upon completion.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

EPI-USE Labs Limited (Registered number: 09302382)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2023

2. ACCOUNTING POLICIES - continued

Tangible fixed assets
Tangible fixed assets are depreciated at annual rates of 10% to 50% on cost.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 32 (2022 - 34 ) .

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 March 2022 191,822
Additions 34,389
At 28 February 2023 226,211
DEPRECIATION
At 1 March 2022 137,204
Charge for year 25,423
At 28 February 2023 162,627
NET BOOK VALUE
At 28 February 2023 63,584
At 28 February 2022 54,618

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
28.2.23 28.2.22
£    £   
Trade debtors 3,003,063 1,351,369
Amounts owed by group undertakings 552,410 580,534
Other debtors 88,945 88,005
3,644,418 2,019,908

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
28.2.23 28.2.22
£    £   
Trade creditors 1,144,182 527,094
Taxation and social security 572,794 174,986
Other creditors 711,405 904,442
2,428,381 1,606,522

EPI-USE Labs Limited (Registered number: 09302382)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2023

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 28.2.23 28.2.22
value: £    £   
100 Ordinary £1 100 100

8. RESERVES
Retained
earnings
£   

At 1 March 2022 1,829,461
Profit for the year 231,786
At 28 February 2023 2,061,247

9. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Ashfaq Sharif BA FCA CTA (Senior Statutory Auditor)
for and on behalf of PB Associates

EPI-USE Labs Limited (Registered number: 09302382)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2023

10. RELATED PARTY DISCLOSURES

During the year the company made sales to group companies as follows:

2023 2022
£ £

EULabs Limited 659,104 1,166,512
EULabs BV Nil Nil
Evolutio PS, LLC Nil 13,595
EPI-USE Limited 387,169 35,070
EPI-USE Labs Limited AE 27,052 -150
G3G 192,941 4,018
EPI-USE Africa (Pty) Ltd 18,707 Nil
EPI-USE Labs LLC 12,050 Nil
EPI-USE Labs ZA 38,931 Nil

During the year the company made purchases from group companies as follows:

2023 2022
£ £

EPI-USE Africa (Pty) Ltd 143,010 243,574
EPI-USE Labs ZA 64,306 Nil
EPI-USE Limited 49,176 62,777
G3G 716,899 226,703
EPI-USE Labs LLC 10,329 1,461
EPI-USE Labs GmbH 173,233 53,519
EULabs Limited 851,209 2,669,696
EPI-USE Switzerland 2,172,185 Nil
EPI-USE America 101,123 Nil
Evolutio PS, LLC 5,460 Nil

At the balance sheet date the following amounts were due to group companies:

2023 2022
£ £

EULabs Limited -15,856 -303,771
EPI-USE Africa (Pty) Ltd -27,399 -95,810
EPI-USE Limited -10,058 -12,094
EPI-USE Labs LLC -3,016 -6,076
G3G Nil -21,822
EPI-USE America -27,275 Nil
EPI-USE Labs GmbH -14,816 Nil
EPI-USE Labs ZA -7,758 Nil
EPI-USE Switzerland -794,122 Nil

At the balance sheet date the following amounts were due from group companies:

2023 2022
£ £


EPI-USE Labs Limited (Registered number: 09302382)

Notes to the Financial Statements - continued
for the Year Ended 28 February 2023
EPI-USE Denmark ApS Nil Nil
EPI-USE Iberia SL Nil Nil
EPI-USE Limited 47,983 74,279
G3G Limited Nil Nil
EULabs BV Nil 580,534
Evolutio PS, LLC Nil Nil
EPI-USE Labs Limited AE 23,575 Nil
EPI-USE Labs ZA 199 Nil
EPI-USE Labs LLC 13,021 Nil

11. ULTIMATE CONTROLLING PARTY

The controlling party is EPI-USE Systems Limited.

There are a number of shareholders in EPI-USE Systems Limited, none of whom hold a controlling interest in the company.